Time to Next Treatment Following Sub-Ablative Progression Directed Radiation Therapy for Oligoprogressive Non-Small-Cell Lung Cancer

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2024 Nov 26

PMID 39590136

Authors

Riccardo Ray Colciago

Chiara Chissotti

Federica Ferrario

Maria Belmonte

Giorgio Purrello

Valeria Faccenda

Denis Panizza

Stefania Canova

Gaia Passarella

Diego Luigi Cortinovis

Stefano Arcangeli

Affiliations

Soon will be listed here.

Abstract

We aimed to evaluate whether progression-directed radiation therapy (PDRT) can prolong the initiation of a subsequent systemic therapy regimen in a cohort of patients with oligoprogressive NSCLC. A retrospective analysis was conducted on NSCLC patients who underwent PDRT for extracranial oligoprogressive NSCLC, defined as limited (up to five) progressing lesions following initial complete, partial, or stable response to systemic therapy according to REC1ST 1.1 and/or PERCIST 1.0 criteria. Cox proportional hazard regressions were performed to identify factors influencing time to next treatment (TTNT), which was considered the primary endpoint. Forty patients were analyzed. First, second, and ≥3 lines of systemic therapy were administered in 22 (58.2%), 14 (27.2%), and 4 (14.6%) cases, respectively. The median total dose was 36 Gy (range: 12-60) in five fractions (1-10), with a median biological effective dose for tumor control (BED10) of 52 Gy (26.4-151.2). After a median follow-up of 11 months (2-50), PDRT delayed further systemic therapy in 32 (80.0%) treatments. Median TTNT was not reached at 8 months (1-47) with a one-year Kaplan-Meier estimate of 81.4% (95% CI: 75.0% to 87.8%). No >grade 3 adverse event was observed. On multivariate analysis, patients with ≥3 lines of systemic therapy and/or with larger CTV volumes did not benefit from PDRT. Despite the use of sub-ablative doses, our findings show that PDRT represents an effective, safe, and viable option for oligoprogressive NSCLC. Patients irradiated early during their systemic treatment course, with a low volume of disease and nonmetastatic oligoprogression, could derive substantial benefits from PDRT.

References

Ost P, Jereczek-Fossa B, van As N, Zilli T, Muacevic A, Olivier K . Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. Eur Urol. 2015; 69(1):9-12. DOI: 10.1016/j.eururo.2015.07.004. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Mavrikios A, Remon J, Quevrin C, Mercier O, Tselikas L, Botticella A . Local control strategies for management of NSCLC with oligoprogressive disease. Cancer Treat Rev. 2023; 120:102621. DOI: 10.1016/j.ctrv.2023.102621. View

Ratnakumaran R, McDonald F . The Management of Oligometastases in Non-small Cell Lung Cancer - is Stereotactic Ablative Radiotherapy now Standard of Care?. Clin Oncol (R Coll Radiol). 2022; 34(11):753-760. DOI: 10.1016/j.clon.2022.08.033. View

Rosner S, Liu C, Forde P, Hu C . Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis. JTO Clin Res Rep. 2022; 3(9):100384. PMC: 9472066. DOI: 10.1016/j.jtocrr.2022.100384. View

Franzese C, Comito T, Toska E, Tozzi A, Clerici E, De Rose F . Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiother Oncol. 2018; 133:220-226. DOI: 10.1016/j.radonc.2018.10.024. View

Fong Y, Fortner J, Sun R, Brennan M, Blumgart L . Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230(3):309-18; discussion 318-21. PMC: 1420876. DOI: 10.1097/00000658-199909000-00004. View

Phillips R, Shi W, Deek M, Radwan N, Lim S, Antonarakis E . Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020; 6(5):650-659. PMC: 7225913. DOI: 10.1001/jamaoncol.2020.0147. View

Kroeze S, Schaule J, Fritz C, Kaul D, Blanck O, Kahl K . Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database. Radiat Oncol. 2021; 16(1):4. PMC: 7788768. DOI: 10.1186/s13014-020-01730-0. View

10.

Iyengar P, Wardak Z, Gerber D, Tumati V, Ahn C, Hughes R . Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2017; 4(1):e173501. PMC: 5833648. DOI: 10.1001/jamaoncol.2017.3501. View

11.

Cuccia F, Mazzola R, Figlia V, Giaj-Levra N, Nicosia L, Ricchetti F . Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors. Strahlenther Onkol. 2022; 198(10):934-939. DOI: 10.1007/s00066-022-01951-0. View

12.

Ruers T, Van Coevorden F, Punt C, Pierie J, Borel-Rinkes I, Ledermann J . Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst. 2017; 109(9). PMC: 5408999. DOI: 10.1093/jnci/djx015. View

13.

Weickhardt A, Scheier B, Burke J, Gan G, Lu X, Bunn Jr P . Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012; 7(12):1807-1814. PMC: 3506112. DOI: 10.1097/JTO.0b013e3182745948. View

14.

Pastorino U, Buyse M, Friedel G, Ginsberg R, Girard P, Goldstraw P . Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997; 113(1):37-49. DOI: 10.1016/s0022-5223(97)70397-0. View

15.

Franceschini D, De Rose F, Franzese C, Comito T, Di Brina L, Radicioni G . Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019; 104(1):111-121. DOI: 10.1016/j.ijrobp.2018.12.049. View

16.

Franceschini D, De Rose F, Cozzi S, Franzese C, Rossi S, Finocchiaro G . The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art. Crit Rev Oncol Hematol. 2020; 148:102894. DOI: 10.1016/j.critrevonc.2020.102894. View

17.

Nicosia L, Franceschini D, Perrone-Congedi F, Casamassima F, Gerardi M, Rigo M . A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study. Radiother Oncol. 2021; 166:92-99. DOI: 10.1016/j.radonc.2021.10.023. View

18.

Schellenberg D, Gabos Z, Duimering A, Debenham B, Fairchild A, Huang F . Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial. Int J Radiat Oncol Biol Phys. 2024; 121(1):28-38. DOI: 10.1016/j.ijrobp.2024.08.031. View

19.

Xu Y, Li H, Fan Y . Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer. Front Oncol. 2021; 11:642883. PMC: 7973268. DOI: 10.3389/fonc.2021.642883. View

20.

Greenwood H, Hassan J, Fife K, Ajithkumar T, Thippu Jayaprakash K . Single-Fraction Stereotactic Ablative Body Radiotherapy for Primary and Extracranial Oligometastatic Cancers. Clin Oncol (R Coll Radiol). 2023; 35(12):773-786. DOI: 10.1016/j.clon.2023.10.049. View